JP2024532836A5 - - Google Patents
Info
- Publication number
- JP2024532836A5 JP2024532836A5 JP2024509425A JP2024509425A JP2024532836A5 JP 2024532836 A5 JP2024532836 A5 JP 2024532836A5 JP 2024509425 A JP2024509425 A JP 2024509425A JP 2024509425 A JP2024509425 A JP 2024509425A JP 2024532836 A5 JP2024532836 A5 JP 2024532836A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- amino acid
- acid sequence
- tgf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110961038.5 | 2021-08-20 | ||
| CN202110961038 | 2021-08-20 | ||
| PCT/CN2022/113882 WO2023020625A1 (zh) | 2021-08-20 | 2022-08-22 | 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532836A JP2024532836A (ja) | 2024-09-10 |
| JP2024532836A5 true JP2024532836A5 (https=) | 2024-11-12 |
Family
ID=85239528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024509425A Pending JP2024532836A (ja) | 2021-08-20 | 2022-08-22 | 抗ＴＩＧＩＴ抗体及びＴＧＦ－βＲを含む融合タンパク質、並びにその医薬組成物及び使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250319169A2 (https=) |
| EP (1) | EP4389771A4 (https=) |
| JP (1) | JP2024532836A (https=) |
| KR (1) | KR20240046905A (https=) |
| CN (1) | CN116003625A (https=) |
| AU (1) | AU2022330896A1 (https=) |
| CA (1) | CA3229166A1 (https=) |
| IL (1) | IL310541A (https=) |
| MX (1) | MX2024002147A (https=) |
| WO (1) | WO2023020625A1 (https=) |
| ZA (1) | ZA202401813B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240002504A1 (en) * | 2020-10-26 | 2024-01-04 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| KR20250151519A (ko) * | 2023-02-20 | 2025-10-21 | 아케소 바이오파마 컴퍼니 리미티드 | TGF-βRII 세포 외 영역 단편을 포함하는 융합 단백질, 및 이의 약제학적 조성물, 및 이의 용도 |
| WO2025056056A1 (zh) * | 2023-09-14 | 2025-03-20 | 中山康方生物医药有限公司 | 药物组合及用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| EP3349792A1 (en) * | 2015-09-14 | 2018-07-25 | Compass Therapeutics LLC | Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf- |
| PE20181046A1 (es) * | 2015-09-25 | 2018-07-03 | Genentech Inc | Anticuerpos anti-tigit y metodos de uso |
| IL299616A (en) * | 2016-01-08 | 2023-03-01 | Univ California | Conditionally active heterodimeric polypeptides and methods of using them |
| US10537633B2 (en) * | 2016-03-04 | 2020-01-21 | Jn Biosciences Llc | Antibodies to TIGIT |
| MY202480A (en) * | 2017-05-12 | 2024-04-30 | Shanghai hengrui pharmaceutical co ltd | Fusion protein containing tgf- receptor and medicinal uses thereof |
| JP7317272B2 (ja) * | 2017-09-29 | 2023-07-31 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | Ｔｉｇｉｔ抗体、その抗原結合断片及びその医療用途 本願は、２０１９年９月２９日に出願された出願番号ｃｎ２０１７１０９０８５６５．３に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。 |
| EP3720881A1 (en) * | 2017-12-08 | 2020-10-14 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| AU2019207296A1 (en) * | 2018-01-15 | 2020-07-16 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against TIGIT |
| WO2020263796A1 (en) * | 2019-06-23 | 2020-12-30 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Anti-alpp car-t cell therapy |
| IL292758A (en) * | 2019-11-05 | 2022-07-01 | Merck Patent Gmbh | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| TW202128763A (zh) * | 2019-11-12 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含有ＴＧＦ－β受體的融合蛋白及其醫藥用途 |
| WO2021101796A1 (en) * | 2019-11-18 | 2021-05-27 | The Brigham And Women's Hospital, Inc. | Codon optimized new generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use |
| US20240002504A1 (en) * | 2020-10-26 | 2024-01-04 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| CN114106182B (zh) * | 2022-01-26 | 2022-05-17 | 中山康方生物医药有限公司 | 抗tigit的抗体及其用途 |
| CN114181310B (zh) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
-
2022
- 2022-08-22 WO PCT/CN2022/113882 patent/WO2023020625A1/zh not_active Ceased
- 2022-08-22 KR KR1020247008893A patent/KR20240046905A/ko active Pending
- 2022-08-22 CA CA3229166A patent/CA3229166A1/en active Pending
- 2022-08-22 JP JP2024509425A patent/JP2024532836A/ja active Pending
- 2022-08-22 IL IL310541A patent/IL310541A/en unknown
- 2022-08-22 CN CN202211006660.1A patent/CN116003625A/zh active Pending
- 2022-08-22 AU AU2022330896A patent/AU2022330896A1/en active Pending
- 2022-08-22 MX MX2024002147A patent/MX2024002147A/es unknown
- 2022-08-22 EP EP22857934.8A patent/EP4389771A4/en active Pending
- 2022-08-22 US US18/684,899 patent/US20250319169A2/en active Pending
-
2024
- 2024-03-01 ZA ZA2024/01813A patent/ZA202401813B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11136413B2 (en) | PDL-1 antibody, pharmaceutical composition thereof, and uses thereof | |
| CN115551888B (zh) | 抗cd73抗体及其用途 | |
| KR102937285B1 (ko) | 신규 항-pd-l1 항체 | |
| CN101868478B (zh) | 巨噬细胞刺激蛋白质受体(ron)的抑制及其治疗方法 | |
| JP2024532836A5 (https=) | ||
| CN114181310B (zh) | 抗tigit抗体、其药物组合物及用途 | |
| AU2018447127A1 (en) | Anti-CLDN128.2 antibody and uses thereof | |
| AU2017279046A1 (en) | Therapeutic uses of a c-Raf inhibitor | |
| JP2023539501A5 (https=) | ||
| JP2022509156A5 (https=) | ||
| CN107614010A (zh) | 结合至flt3蛋白的抗体药物偶联物(adc) | |
| JP2023546743A5 (https=) | ||
| JP2024538669A5 (https=) | ||
| JP2025511289A5 (https=) | ||
| JP2025511288A5 (https=) | ||
| EP4506360A1 (en) | Anti-pvrig antibody, pharmaceutical composition thereof and use thereof | |
| CN116925233A (zh) | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 | |
| JP2024533457A5 (https=) | ||
| JP2024508597A5 (https=) | ||
| WO2016163433A1 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| RU2024103139A (ru) | Слитый белок, содержащий антитело против TIGIT и TGF-βR, фармацевтическая композиция и ее применение | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| RU2025124380A (ru) | СЛИТЫЙ БЕЛОК, СОДЕРЖАЩИЙ ФРАГМЕНТ ВНЕКЛЕТОЧНОЙ ОБЛАСТИ TGF-βRII, ЕГО ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЕГО ПРИМЕНЕНИЕ | |
| HK40089230A (zh) | 药物组合物及用途 | |
| KR20250169615A (ko) | 항-ctla4 및 항-pd-1 이중특이성 항체의 의학적 용도 |